With over fifteen years of experience in US funded biotech companies, and seven years of company, compound and technology profiling, Jesse Paterson performs strategic analysis of internal and potential collaboration opportunities, including scientific and business evaluations. Jesse has a broad perspective of drug R&D & commercialization process, license, option, research, material transfer & confidentiality agreements. He specializes in reviews of scientific literature, summaries of current market dynamics, including qualitative and quantitative market research.
In 2000, Jesse was part of the founding team that successfully funded and spun out Xanthus Pharmaceuticals from McGill University. In 2009, he joined Angiochem, to identify potential partners and negotiate partnering/collaboration agreements. He participated in the closure of deals including out-licensing of a phase one oncology compound, and discovery level research collaborations with GSK and Genzyme. His therapeutic areas include: Oncology, CNS, Rare Diseases and Women’s Health.
Jesse has a B.Sc. in Biochemistry from Concordia University and M.Sc. in Experimental Medicine from McGill University.